We are live on ! Find out more
ZNTL icon

Zentalis Pharmaceuticals
ZNTL

61 hedge funds and large institutions have $1.28B invested in Zentalis Pharmaceuticals in 2020 Q2 according to their latest regulatory filings, with 61 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

74.86% more ownership

Funds ownership: 0% → 74.86% (+75%)

Holders
61
Holders Change
+61
Holders Change %
–
% of All Funds
1.25%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
61
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
Viking Global Investors
Viking Global Investors
Connecticut
+$170M
2
MCMC
Matrix Capital Management Company
New Hampshire
+$147M
3
TCM
Tybourne Capital Management
Hong Kong
+$102M
4
Fidelity Investments
Fidelity Investments
Massachusetts
+$88.6M
5
RG
Redmile Group
California
+$63.7M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
Viking Global Investors
1
Viking Global Investors
Connecticut
$213M +$170M +4,443,284 New
MCMC
2
Matrix Capital Management Company
New Hampshire
$184M +$147M +3,821,739 New
TCM
3
Tybourne Capital Management
Hong Kong
$128M +$102M +2,664,409 New
Fidelity Investments
4
Fidelity Investments
Massachusetts
$111M +$88.6M +2,310,946 New
RG
5
Redmile Group
California
$79.8M +$63.7M +1,661,205 New
Citadel Advisors
6
Citadel Advisors
Florida
$74.9M +$59.9M +1,560,687 New
T. Rowe Price Associates
7
T. Rowe Price Associates
Maryland
$57M +$45.5M +1,187,566 New
FCM
8
Farallon Capital Management
California
$47.6M +$38M +991,174 New
PA
9
Perceptive Advisors
New York
$45.8M +$40.3M +1,050,003 New
BlackRock
10
BlackRock
New York
$43.8M +$35M +912,549 New
EAM
11
Eventide Asset Management
Massachusetts
$42.5M +$35.1M +914,705 New
Vanguard Group
12
Vanguard Group
Pennsylvania
$39.7M +$31.7M +826,942 New
APM
13
Avidity Partners Management
Texas
$32.4M +$25.9M +674,487 New
Primecap Management
14
Primecap Management
California
$31.7M +$25.3M +659,950 New
AllianceBernstein
15
AllianceBernstein
Tennessee
$23.9M +$19.1M +498,272 New
Capital World Investors
16
Capital World Investors
California
$21.6M +$17.3M +450,000 New
MC
17
Mayo Clinic
Minnesota
$21.3M +$17M +442,713 New
Invesco
18
Invesco
Georgia
$13.3M +$10.6M +277,393 New
Geode Capital Management
19
Geode Capital Management
Massachusetts
$7.79M +$6.23M +162,335 New
Franklin Resources
20
Franklin Resources
California
$7.38M +$6.71M +175,050 New
SAM
21
Sectoral Asset Management
Quebec, Canada
$6.92M +$5.53M +144,200 New
State Street
22
State Street
Massachusetts
$6.59M +$5.26M +137,270 New
Northern Trust
23
Northern Trust
Illinois
$6.36M +$5.08M +132,536 New
Axa
24
Axa
France
$5.12M +$4.09M +106,643 New
AG
25
Artal Group
Luxembourg
$4.42M +$3.53M +92,000 New
1
2 3

ZNTL Hedge Fund Activity: Q2 2020 in Review

61 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Zentalis Pharmaceuticals (ZNTL) for Q2 2020, worth a combined $1.28B.

Buyers outnumbered sellers: 61 funds opened new ZNTL positions and 0 closed out — a net gain of 61 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Viking Global Investors, opening a new position worth an estimated $170M.

  • 61 institutional investors held Zentalis Pharmaceuticals (ZNTL) as of Q2 2020, up from 0 in Q1 2020.
  • Funds reported $1.28B of Zentalis Pharmaceuticals stock for Q2 2020.
  • 61 funds opened new Zentalis Pharmaceuticals positions in Q2 2020 and 0 closed out, a net change of +61 holders.
  • The largest Zentalis Pharmaceuticals buyer in Q2 2020 was Viking Global Investors, an estimated $170M added.

Based on aggregated 13F filings for Q2 2020.